+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A 12-week, double-blind, multicenter study comparing diflunisal twice daily and ibuprofen four times daily in the treatment of rheumatoid arthritis



A 12-week, double-blind, multicenter study comparing diflunisal twice daily and ibuprofen four times daily in the treatment of rheumatoid arthritis



Clinical Therapeutics 9 Suppl C: 27-36



Diflunisal, a nonacetylated salicylate preparation with a prolonged duration of action, was compared with ibuprofen for the treatment of rheumatoid arthritis in a multicenter trial comprising 210 patients. Diflunisal was administered twice a day (500 to 750 mg/day) and ibuprofen was administered four times a day (1,600 to 2,400 mg/day). To maintain double-blind conditions, all patients ostensibly followed the same regimen, ingesting their assigned drug and a matching placebo of their nonassigned drug. Disease activity assessments and laboratory tests were done periodically throughout the 12 weeks of the study, and results were compared with pretreatment findings. Efficacy evaluations in 187 patients showed that both treatments were similarly efficacious. Safety and tolerability also were similar in the two groups. Diflunisal, however, offers a more acceptable BID treatment schedule.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039025011

Download citation: RISBibTeXText

PMID: 3548984


Related references

Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three times daily dosage schedules. Journal of Clinical Psychopharmacology 15(4 Suppl 2): 4s-9s, 1995

Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules. Clinical Neuropharmacology 17(Suppl. 1): S1-S8, 1994

Diflunisal in the treatment of osteoarthrosis: a double-blind study comparing diflunisal with ibuprofen. Current Medical Research and Opinion 5(7): 556-561, 1978

A double blind multicenter study of sulindac once daily versus sulindac twice daily in rheumatoid arthritis. Current Therapeutic Research 41(5): 679-691, 1987

Tu1052 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Tak-438 (10 mg or 20 mg Once-Daily) Compared to Lansoprazole (15 mg Once-Daily) in a 24-Week Maintenance Treatment for Healed Erosive Esophagitis. Gastroenterology 146(5): S-738, 2014

One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Diseases 18(10): 1885-1893, 2012

One-year investigator-blind randomized multicenter trial comparing asacol 24 g once daily with 8 mg three times daily for maintenance of remission in ulcerative colitis. 2012

Ibuprofen and diflunisal in rheumatoid arthritis: a double-blind comparative trial. New Zealand Medical Journal 94(688): 45-47, 1981

Sa1217 Once Daily Dosing of 9mg Budesonide (Budenofalk) Is Therapeutic Equivalent to a Three-Times Daily Dosing of 3mg Budesonide for the Treatment of Active Crohn's Disease: A Randomized, Double-Blind, Double-Dummy, Multicenter Phase Iii Study. Gastroenterology 144(5): S-233, 2013

Double-masked double-dummy multicenter study comparing Lomefloxacin 03 percent twice daily with norfloxacin 03 percent four times daily in patients with acute bacterial conjunctivitis. IOVS 39(4): S140, 1998

An international multicenter collaborative trial comparing cimetidine 800 mg twice daily and 400 mg four times daily in the treatment of reflux esophagitis. Current Therapeutic Research 44(4): 646-657, 1988

Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. Journal of Rheumatology 29(3): 436-446, 2002

A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. British Journal of Rheumatology 35(Suppl. 1): 22-28, 1996

Double blind comparative multicenter study of the efficacy and safety of a slow release tablet of 200 mg ketoprofen once daily and a 50 mg ketoprofen capsule four times daily. Current Therapeutic Research 40(6): 1129-1146, 1986

Treatment of Acute Maxillary Sinusitis with Bacampicillin Twice Daily or three Times Daily. A Double Blind Comparison. Acta Oto-Laryngologica 93(Sup386): 268-269, 1982